Charge heterogeneity in monoclonal antibodies can negatively impact binding affinity and potency, so it is critical to ensure that individual charge variants of biotherapeutic molecules are thoroughly ...
Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. Background: MGD009 is a B7-H3 x CD3 ...
Surface plasmon resonance (SPR) technology is expanding strategies for studying and analyzing binding kinetics, offering real-time, label-free analysis. Researchers at the “Developments in Protein ...
Fragment-based drug discovery (FBDD) has gained widespread recognition as a valuable approach in the search for lead drug candidates in drug discovery programs. It is utilized in conjunction with ...
SEATTLE, WA / ACCESSWIRE / December 2, 2020 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology ...
Real-time, label-free binding analysis is often viewed incorrectly as an ‘art’ instead of a ‘science’. The Octet® SF3 system challenges this notion through user-friendly technology. The field of ...
Ryan Denomme, the CEO of Nicoya, speaks to News-Medical on their SARS-CoV-2 research using their SPR technology. At Nicoya, our mission is to improve human life by helping scientists succeed. Given ...
TEMPE, Ariz.--(BUSINESS WIRE)--Biosensing Instrument Inc (BI) introduced the SPRm 200, the world’s first commercially available surface plasmon resonance microscopy (SPRM) system. The new SPRm 200 is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results